Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $65.00 target price on the stock. Cantor Fitzgerald’s target price points to a potential upside of 77.89% from the stock’s previous close.

Separately, Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $85.71.

Structure Therapeutics Price Performance

Shares of GPCR traded down $0.53 during mid-day trading on Thursday, reaching $36.54. 34,919 shares of the company’s stock were exchanged, compared to its average volume of 574,664. The stock has a market capitalization of $1.70 billion and a PE ratio of -44.18. The business’s fifty day simple moving average is $41.02 and its 200-day simple moving average is $48.70. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. Equities research analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC acquired a new stake in Structure Therapeutics in the fourth quarter valued at $28,000. Tower Research Capital LLC TRC increased its position in shares of Structure Therapeutics by 1,274.6% in the third quarter. Tower Research Capital LLC TRC now owns 921 shares of the company’s stock valued at $46,000 after buying an additional 854 shares in the last quarter. Barclays PLC purchased a new position in shares of Structure Therapeutics in the second quarter valued at $47,000. Picton Mahoney Asset Management purchased a new position in shares of Structure Therapeutics in the third quarter valued at $116,000. Finally, Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at $139,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.